articleTop 1% cited

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

Cancer Cell · 2014 · Vol. 25(2) · pp. 152–165

Woonyoung Choi(The University of Texas MD Anderson Cancer Center)Sima P. Porten(The University of Texas MD Anderson Cancer Center)Seungchan Kim(Translational Genomics Research Institute)Daniel Willis(The University of Texas MD Anderson Cancer Center)Elizabeth R. Plimack(Fox Chase Cancer Center)Jean Hoffman‐Censits(Thomas Jefferson University Hospital)Beat Roth(The University of Texas MD Anderson Cancer Center)Tiewei Cheng(University of Houston)Mai Tran(University of Houston)I-Ling Lee(The University of Texas MD Anderson Cancer Center)Jonathan Melquist(The University of Texas MD Anderson Cancer Center)Jolanta Bondaruk(The University of Texas MD Anderson Cancer Center)Tadeusz Majewski(The University of Texas MD Anderson Cancer Center)Shizhen Zhang(The University of Texas MD Anderson Cancer Center)Shanna Pretzsch(The University of Texas MD Anderson Cancer Center)Keith Baggerly(The University of Texas MD Anderson Cancer Center)Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center)Bogdan Czerniak(The University of Texas MD Anderson Cancer Center)Colin P. Dinney(The University of Texas MD Anderson Cancer Center)David J. McConkey✉(The University of Texas MD Anderson Cancer Center)

View via DOI Publisher page

Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology Studies Cancer Immunotherapy and BiomarkersBladder cancerChemotherapyVinblastineCisplatinBreast cancerCancer researchBiologyOncologyDiseaseInternal medicine

MeSH terms

AgedAntineoplastic Combined Chemotherapy ProtocolsUrinary Bladder NeoplasmsCarcinoma, Basal CellBasal Cell CarcinomaCarcinoma, Squamous CellCell DifferentiationCisplatinDoxorubicinFemaleHumansMaleMethotrexateMutationNeoplasm Invasiveness